Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

267.79 +2.27 (+0.85%)
Streaming Delayed Price Updated: 2:22 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 979,721
Open 264.74
Bid (Size) 267.64 (4)
Ask (Size) 267.87 (2)
Prev. Close 265.52
Today's Range 263.50 - 268.11
52wk Range 211.71 - 288.46
Shares Outstanding N/A
Dividend Yield 3.18%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings for Amgen
Via Benzinga
1 Spectacular Dividend Stock Every Investor Should Consider
This biotech pioneer has been an exceptional growth and income stock. 
Via The Motley Fool

Performance

YTD
+2.35%
+2.35%
1 Month
+1.75%
+1.75%
3 Month
+3.14%
+3.14%
6 Month
+22.54%
+22.54%
1 Year
-5.25%
-5.25%

More News

Read More
Why NASDAQ:AMGN is a Top Pick for Dividend Investors.
Via Chartmill
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
Via Benzinga
P/E Ratio Insights for Amgen
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
Via The Motley Fool
20 Analysts Have This to Say About Amgen
Via Benzinga
Amgen's Rare Autoimmune Disease Candidate Shows Improvement In Disease Burden In Treating Sjögren's Syndrome
Via Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Via Investor's Business Daily
Amgen Wins Big With FDA, Analyst Sees Soaring Potential
Via Benzinga
Exposures Product Safety
Earnings Outlook For Amgen
Via Benzinga
These Analysts Revise Their Forecasts On Amgen After Q3 Results
Via Benzinga
5 Dow stocks to track during the market correction
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via FinancialNewsMedia
Investor patience tested as pharmaceutical stocks take a tumble
Via MarketBeat
Fear & Greed Index Remains In 'Fear' Zone Ahead Of Fed's Decision
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Treasury Announcement More Important Than Fed's, Japan Abandons Yield Control, Tesla Under $200
Via Benzinga
Topics Economy
Exposures Interest Rates
Amgen Lifts Annual Outlook After Q3 Performance, But Stock Still Falls - Here's Why
Via Benzinga
Amgen Boosts Outlook Following Horizon Takeover, But Dips On Light Enbrel Sales
Via Investor's Business Daily
U.S. Stocks Poised To Extend Gains As Fed Meeting Gets Underway; Why This Analyst Expects 'Young Bull Market' To Remain Alive
Via Benzinga
Topics Economy
Exposures Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.